These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32081857)

  • 1. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
    Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
    Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer.
    Yu X; Gao F; Li W; Zhou L; Liu W; Li M
    J Exp Clin Cancer Res; 2020 Apr; 39(1):62. PubMed ID: 32276600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
    Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
    Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.
    Li W; Yu X; Tan S; Liu W; Zhou L; Liu H
    Cancer Med; 2018 Jan; 7(1):208-218. PubMed ID: 29239135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
    Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.
    Jung SK; Lee MH; Lim DY; Kim JE; Singh P; Lee SY; Jeong CH; Lim TG; Chen H; Chi YI; Kundu JK; Lee NH; Lee CC; Cho YY; Bode AM; Lee KW; Dong Z
    J Biol Chem; 2014 Dec; 289(52):35839-48. PubMed ID: 25368326
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
    Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.
    Xie YJ; Gao WN; Wu QB; Yao XJ; Jiang ZB; Wang YW; Wang WJ; Li W; Hussain S; Liu L; Leung EL; Fan XX
    Pharmacol Res; 2020 Sep; 159():104934. PubMed ID: 32464330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological basis and new insights of deguelin concerning its anticancer effects.
    Lin ZY; Yun QZ; Wu L; Zhang TW; Yao TZ
    Pharmacol Res; 2021 Dec; 174():105935. PubMed ID: 34644595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
    J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.
    Li W; Gao F; Ma X; Wang R; Dong X; Wang W
    Oncotarget; 2017 May; 8(20):32586-32599. PubMed ID: 28427230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.
    Lin L; Ding D; Xiao X; Li B; Cao P; Li S
    J Cell Mol Med; 2020 Jun; 24(12):6822-6832. PubMed ID: 32352219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
    Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.
    Hu C; Wang A; Wu H; Qi Z; Li X; Yan XE; Chen C; Yu K; Zou F; Wang W; Wang W; Wu J; Liu J; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
    Oncotarget; 2017 Mar; 8(11):18359-18372. PubMed ID: 28407693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
    Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
    Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.